Patent: 9,963,452
✉ Email this page to a colleague
Summary for Patent: 9,963,452
Title: | Methods, compounds, and compositions for inhibition of ROS |
Abstract: | The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I). ##STR00001## |
Inventor(s): | Grueneberg; Dorre A. (Newton, MA), Kalid; Ori (Pardes-Hanna, IL), Xian; Jun (Sharon, MA), Rajur; Sharanappa B. (Andover, MA), Kim; Hwa-Ok (Lexington, MA), Neelagiri; Venugopal Rao (Acton, MA), Salgaonkar; Paresh (Medford, MA), Sethumadhavan; Divakaramenon (Waltham, MA), Moon; Chaeho (Burlington, MA), Neelagiri; Madhavi (Acton, MA) |
Assignee: | AUGUSTA PHARMACEUTICALS INC. (Newton, MA) |
Application Number: | 14/775,825 |
Patent Claims: | see list of patent claims |
Details for Patent 9,963,452
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2033-03-14 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2033-03-14 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2033-03-14 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2033-03-14 | |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-03-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-03-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |